ADORA2A and Parkinson disease: Directly blocking A2AR with SCH58261 phenocopied this increased impact of ATP-derived adenosine on LTP magnitude during the presymptomatic PD period (Fig. 6I), as heralded by the larger inhibition of corticostriatal LTP magnitude caused by 50 nM SCH58261 (F1,20 = 8.302, p < 0.05) in slices from rats 7 days after 6-OHDA exposure (65.59 ± 10.87% inhibition, n = 6) compared to vehicle-injected rats (40.71 ± 3.77% inhibition, n = 6) (Fig. 6I, J).